← Patent-cliff monitor small molecule TRYVIO APROCITENTAN
Loss of exclusivity July 2038 latest FDA-listed patent expiry
Company Idorsia → See this company's full patent-cliff portfolio Drug detail Brand name TRYVIO Active ingredient APROCITENTAN Strength 12.5MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval March 2024 Marketing status RX
Listed patents Patent Expires Type 11680058 July 2038 use U-3878 11787782 March 2038 use U-3877 12297189 February 2038 product 10919881 February 2038 substance, product 11174247 November 2037 use U-3879 8324232 September 2029 substance, product
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.